China
-
AstraZeneca acquires full rights to liver cancer therapy in USD630M deal with AbelZeta
AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.
-
Zai Lab secures China approval for Augtyro to treat NTRK fusion-positive solid tumors
The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.
-
Everest Medicines announces ambitious 2030 growth strategy as leadership raises stakes
Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.
-
Everest Medicines expands its cardiovascular portfolio through strategic collaboration with Hasten Biopharmaceuticals
The collaboration is designed to strengthen Everest’s commercial operations in China while expanding its presence in the cardiovascular disease market.
-
Pfizer strengthens obesity drug pipeline with USD2B licensing deal with YaoPharma
YaoPharma stands to earn as much as USD1.94 billion in additional milestone payments tied to development, regulatory, and commercial achievements.
-
The Herbal Divide: Why Asia embraces traditional medicine, while the West holds back
Herbal medicine is extremely popular among the Chinese public for both prevention and treatment, but unlike many Western countries, China has policies designed to address a growing disease burden among an aging population and wholeheartedly supports the use of herbal medicines.